Sept. 9, 2022
/PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Nantucket Therapeutics Conference,
Raj Mehra, Ph.D., Chairman and CEO will hold 1×1 investor meetings and participate in a fireside chat hosted by Senior Biotechnology Analyst
Wednesday, September 28
2:45 PM ET
Webcast of the fireside chat may be accessed
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.
, the content of which is not incorporated herein by reference.
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2
New York, NY
Mike Moyer Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY
View original content to download multimedia:
SOURCE Seelos Therapeutics, Inc.